- Home
- ICON vs MTNB Comparison
ICON vs MTNB Comparison
Compare ICON & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- MTNB
- Stock Information
- Founded
- ICON 2023
- MTNB 2013
- Country
- ICON Greece
- MTNB United States
- Employees
- ICON N/A
- MTNB N/A
- Industry
- ICON
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- ICON
- MTNB Health Care
- Exchange
- ICON Nasdaq
- MTNB Nasdaq
- Market Cap
- ICON 3.6M
- MTNB 3.6M
- IPO Year
- ICON 2024
- MTNB N/A
- Fundamental
- Price
- ICON $1.79
- MTNB $0.87
- Analyst Decision
- ICON Strong Buy
- MTNB Hold
- Analyst Count
- ICON 1
- MTNB 1
- Target Price
- ICON $4.50
- MTNB N/A
- AVG Volume (30 Days)
- ICON 116.0K
- MTNB 125.5K
- Earning Date
- ICON 05-23-2025
- MTNB 05-27-2025
- Dividend Yield
- ICON 195.06%
- MTNB N/A
- EPS Growth
- ICON N/A
- MTNB N/A
- EPS
- ICON N/A
- MTNB N/A
- Revenue
- ICON $5,309,000.00
- MTNB N/A
- Revenue This Year
- ICON $76.76
- MTNB N/A
- Revenue Next Year
- ICON $30.43
- MTNB N/A
- P/E Ratio
- ICON N/A
- MTNB N/A
- Revenue Growth
- ICON 18.61
- MTNB N/A
- 52 Week Low
- ICON $1.60
- MTNB $0.48
- 52 Week High
- ICON $154.00
- MTNB $9.60
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- MTNB 72.55
- Support Level
- ICON N/A
- MTNB $0.60
- Resistance Level
- ICON N/A
- MTNB $0.84
- Average True Range (ATR)
- ICON 0.00
- MTNB 0.09
- MACD
- ICON 0.00
- MTNB 0.02
- Stochastic Oscillator
- ICON 0.00
- MTNB 85.11
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a Growth-oriented company that operates as a holding company for the purpose of acquiring, owning, chartering and operating dry bulk vessels through its subsidiaries. The company generates its revenues by chartering the Initial Vessels to regional and international dry bulk operators, commodity traders and end users.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.